A recent survey of AARP members conducted by Morning Consult that was commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows that 86% of them agree with the Trump Administration’s proposal to reform the rebate rule for Medicare Part D.
Pharmacy benefit managers (PBM), manage drug benefits for insurance companies and other third-party payers. They essentially act as middlemen between insurance companies and consumers in the drug supply chain. In order to gain access to their contracts, which can range into the millions of lives, pharmaceutical manufacturers must pay rebates to PBMs.
The Trump Administration is proposing that pharmacy benefit managers share these rebates at the point of purchase with seniors who have Medicare Part D in order to reduce their drug costs, which is something AMAC wholeheartedly supports.
AARP, however, has consistently opposed this rule, despite this survey showing overwhelming support for it by their rank and file membership. The survey also showed that 85% of AARP members were disappointed with the organization’s stance on this issue.
Robert Zirkelbach, executive vice president of public affairs for PhRMA said of AARP’s position on the rebate rule, “We are fighting to lower costs for seniors by forcing insurance companies and middlemen to share negotiated savings at the pharmacy counter… yet AARP is choosing to stand with insurance companies rather than their own members. It begs the question: Who is AARP really fighting for?”
Read more about the survey here.